Article Details

Humacyte receives third FDA RMAT for blood vessel product - Investing.com

Retrieved on: 2024-07-01 16:43:54

Tags for this article:

Click the tags to see associated articles and topics

Humacyte receives third FDA RMAT for blood vessel product - Investing.com. View article details on hiswai:

Excerpt

(NASDAQ:HUMA), a biotechnology firm, announced it has been awarded a third Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. ...

Article found on: www.investing.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up